ICMJE DISCLOSURE FORM

Date: March 18th, 2022

Your Name: Yinning Xu

Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| Number | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| 1      | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021KY019), the Chinese Medicine Research Program of |
|        | **No time limit for this item.**                                                                 |                                                                                      |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|---------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
|   |   |   |
|---|---|---|
| 8 | Patents planned, issued or pending | ☑ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ☑ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ☑ None |
| 11 | Stock or stock options | ☑ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ☑ None |
| 13 | Other financial or non-financial interests | ☑ None |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022__________________________

Your Name: Xiaoping Hu

Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Manuscript number (if known): __________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZZQ012, 2021ZA006, 2021ZZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

| Time frame: past 36 months |
|-----------------------------|
| 2  | Grants or contracts from any entity (if not indicated in item #1 above). | ✔️ | None |
| 3  | Royalties or licenses | ✔️ | None |
| 4  | Consulting fees | ✔️ | None |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✔️ | None |
| 6  | Payment for expert testimony | ✔️ | None |
| 7  | Support for attending meetings and/or travel | ✔️ | None |
|   | Patents planned, issued or pending |   |
|---|----------------------------------|---|
| 8 | None                             | _✓_ None |

|   | Participation on a Data Safety Monitoring Board or Advisory Board |   |
|---|------------------------------------------------------------------|---|
| 9 | None                                                             | _✓_ None |

|   | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
|---|----------------------------------------------------------------------------------------------------------------|---|
| 10| None                                                                                                       | _✓_ None |

|   | Stock or stock options |   |
|---|------------------------|---|
| 11| None                                                               | _✓_ None |

|   | Receipt of equipment, materials, drugs, medical writing, gifts or other services |   |
|---|-----------------------------------------------------------------------------------------------------------------|---|
| 12| None                                                                                                            | _✓_ None |

|   | Other financial or non-financial interests |   |
|---|------------------------------------------|---|
| 13| None                                    | _✓_ None |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022___________________________

Your Name: Yiwen Zhang

Manuscript Title: __ Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis._____________

Manuscript number (if known): ____________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| No. | Relationship or Activity | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----|--------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of | Time frame: Since the initial planning of the work |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|-----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ✔️ None |
| 3 | Royalties or licenses | ✔️ None |
| 4 | Consulting fees | ✔️ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✔️ None |
| 6 | Payment for expert testimony | ✔️ None |
| 7 | Support for attending meetings and/or travel | ✔️ None |
|   | Conflict of Interest                                                   |
|---|---------------------------------------------------------------------|
| 8 | Patents planned, issued or pending                                   |
|   | _✓_ None                                                             |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board   |
|   | _✓_ None                                                             |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |
|   | _✓_ None                                                             |
| 11| Stock or stock options                                              |
|   | _✓_ None                                                             |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services |
|   | _✓_ None                                                             |
| 13| Other financial or non-financial interests                           |
|   | _✓_ None                                                             |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018Z2006, 2020Z2003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022Z2001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

___ X ___ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: March 18th, 2022
Your Name: Zongfu Pan
Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.
Manuscript number (if known): ___________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|-----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ✔️ None |
| 3 | Royalties or licenses | ✔️ None |
| 4 | Consulting fees | ✔️ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✔️ None |
| 6 | Payment for expert testimony | ✔️ None |
| 7 | Support for attending meetings and/or travel | ✔️ None |
|   | Question                                                                 | Answer |
|---|--------------------------------------------------------------------------|--------|
| 8 | Patents planned, issued or pending                                       | ✔️ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board        | ✔️ None |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ✔️ None |
| 11| Stock or stock options                                                   | ✔️ None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | ✔️ None |
| 13| Other financial or non-financial interests                                | ✔️ None |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018Z006, 2020Z003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022Z001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 821731437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022_
Your Name: Zhiyong Sun
Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.
Manuscript number (if known): 

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|---------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ✔️ None |
| 3 | Royalties or licenses | ✔️ None |
| 4 | Consulting fees | ✔️ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✔️ None |
| 6 | Payment for expert testimony | ✔️ None |
| 7 | Support for attending meetings and/or travel | ✔️ None |
|   | Patents planned, issued or pending |   |
|---|-----------------------------------|---|
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
| 11 | Stock or stock options |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services |   |
| 13 | Other financial or non-financial interests |   |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 20214443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).
ICMJE DISCLOSURE FORM

Date: __March 18th__, 2022

Your Name: __Zhongjie Huang__

Manuscript Title: __Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.__

Manuscript number (if known): __________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------|----------------------------------------------------------------------------------|
| 1 | __All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item._ | __Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of__ |

Time frame: Since the initial planning of the work
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 821101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|---------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ✔️ None |
| 3 | Royalties or licenses | ✔️ None |
| 4 | Consulting fees | ✔️ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✔️ None |
| 6 | Payment for expert testimony | ✔️ None |
| 7 | Support for attending meetings and/or travel | ✔️ None |
|   |   |   |
|---|---|---|
| 8 | Patents planned, issued or pending | _✓_ None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | _✓_ None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | _✓_ None |
| 11 | Stock or stock options | _✓_ None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _✓_ None |
| 13 | Other financial or non-financial interests | _✓_ None |

Please summarize the above conflict of interest in the following box:

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZQ006, 2020ZQ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZQ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022__
Your Name: _Shuilian Zheng_

Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021Q012, 2021ZA006, 2021Q012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|---------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
|   | Description                                                                 | Answer |
|---|-----------------------------------------------------------------------------|--------|
| 8 | Patents planned, issued or pending                                           | None   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board            | None   |
| 10| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| 11| Stock or stock options                                                       | None   |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| 13| Other financial or non-financial interests                                   | None   |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZQ006, 2020ZQ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZQ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18__th, 2022

Your Name: Hansheng Pan

Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| # | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------|------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021Q012, 2021ZA006, 2021Q012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

|   | Time frame: past 36 months |
|---|-----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | ✓ None |
| 3 | Royalties or licenses | ✓ None |
| 4 | Consulting fees | ✓ None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ✓ None |
| 6 | Payment for expert testimony | ✓ None |
| 7 | Support for attending meetings and/or travel | ✓ None |
|   | Patents planned, issued or pending |   |
|---|----------------------------------|---|
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board |   |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid |   |
| 11 | Stock or stock options |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services |   |
| 13 | Other financial or non-financial interests |   |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021Q012, 2021ZA006, 2021ZZ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

__X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022_____________________
Your Name: Xiaozhou Zou
Manuscript Title: *Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.*
Manuscript number (if known): ____________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | **Funding:** This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
|   | Grants or contracts from any entity (if not indicated in item #1 above). |
|---|---------------------------------------------------------------------|
| 2 | 🚗 None                                                              |

|   | Royalties or licenses                                               |
|---|---------------------------------------------------------------------|
| 3 | 🚗 None                                                              |

|   | Consulting fees                                                    |
|---|---------------------------------------------------------------------|
| 4 | 🚗 None                                                              |

|   | Payment or honoraria for lectures, presentations, speakers bureaus, |
|---|---------------------------------------------------------------------|
| 5 | manuscript writing or educational events                            |
|   | 🚗 None                                                              |

|   | Payment for expert testimony                                       |
|---|---------------------------------------------------------------------|
| 6 | 🚗 None                                                              |

|   | Support for attending meetings and/or travel                        |
|---|---------------------------------------------------------------------|
| 7 | 🚗 None                                                              |
| Question                                                                 | Answer |
|------------------------------------------------------------------------|--------|
| Patents planned, issued or pending                                     | None   |
| Participation on a Data Safety Monitoring Board or Advisory Board      | None   |
| Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None   |
| Stock or stock options                                                 | None   |
| Receipt of equipment, materials, drugs, medical writing, gifts or other services | None   |
| Other financial or non-financial interests                              | None   |

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018Z006, 2020Z003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022Z2001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

__ X __ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __March 18th, 2022__

Your Name: Ping Huang

Manuscript Title: Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Manuscript number (if known): _______________________________________________________________________

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of |
Zhejiang Province (No. 2018ZZ006, 2020ZZ003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022ZZ001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

| Time frame: past 36 months |
|----------------------------|
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None |
| 3 | Royalties or licenses | None |
| 4 | Consulting fees | None |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
|   | Question                                                                 | Answer |
|---|--------------------------------------------------------------------------|--------|
|8  | Patents planned, issued or pending                                       | ✔️ None|
|9  | Participation on a Data Safety Monitoring Board or Advisory Board        | ✔️ None|
|10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ✔️ None|
|11 | Stock or stock options                                                   | ✔️ None|
|12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ✔️ None|
|13 | Other financial or non-financial interests                               | ✔️ None|

Please summarize the above conflict of interest in the following box:

This study was supported by grants from the National Natural Science Foundation of China (No. 82100061 and 82173855), the Zhejiang Province Natural Science Foundation of China (No. LQ21H310004, LY20H310001, and No. LQ21H310005), the Medical and Health Research Program of Zhejiang (No. 2021443880 and 2021KY019), the Chinese Medicine Research Program of Zhejiang Province (No. 2018Z2006, 2020Z2003, 2021ZQ012, 2021ZA006, 2021ZQ012, and 2022Z2001), the “10000 Talents Plan” of Zhejiang Province to Ping Huang (No. 2020R52029), the National Natural Science Foundation of China and the Swedish Research Council Cooperative Research Project (No. 8211101233), the National Natural Science Foundation of China (No. 8217131437), and the Zhejiang Provincial Science and Technology Department’s “top soldier” and “leading wild goose” R & D project (No. 2022C03116).

Please place an “X” next to the following statement to indicate your agreement:

❌ X ✔️ I certify that I have answered every question and have not altered the wording of any of the questions on this form.